These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31498127)

  • 1. Safety Profile of Opicapone in the Management of Parkinson's Disease.
    Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
    J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
    JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
    Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The launch of opicapone for Parkinson's disease: negatives versus positives.
    Castro Caldas A; Teodoro T; Ferreira JJ
    Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
    Żegleń M; Śladowska K; Kawalec P; Brzostek T
    J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.
    Ferreira JJ; Lee JY; Ma HI; Jeon B; Poewe W; Antonini A; Stocchi F; Rodrigues DM; Fonseca MM; Castilla-Fernández G; Holenz J; Rocha JF; Rascol O;
    J Neurol; 2024 Oct; 271(10):6729-6738. PubMed ID: 39164557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opicapone for the treatment of Parkinson's disease: a review.
    Feldman M; Margolesky J
    Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
    [No Abstract]   [Full Text] [Related]  

  • 18. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
    Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
    Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.